43. Park L. S., Waldron P. E., Friend D., Sassenfeld H. M., Price V., Anderson D., Cosman D., Andrews R. G., Bernstein I. D., Urdal D. L. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell traces and major leukemia cells: receptor heterogeneity and relationship to progress factor responsiveness. 28. Kaushansky K., Shoemaker S. G., Alfaro S., Brown C. Hematopoietic exercise of granulocyte/macrophage colony-stimulating issue depends upon two distinct regions of the molecule: useful evaluation based mostly upon the activities of interspecies hybrid development components. 3. Berkner K., Busby S., Davie E., Hart C., Insley M., Kisiel W., Kumar A., Murray M., O’Hara P., Woodbury R. Isolation and expression of cDNAs encoding human issue VII. 53. Ziltener H. J., Clark-Lewis I., Fazekas de St Groth B., Orban P. C., Hood L. E., Kent S. B., Schrader J. W. Monoclonal antipeptide antibodies recognize IL-three and neutralize its bioactivity in vivo. Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment however is insufficient for receptor activation. 39. Otsuka T., Miyajima A., Brown N., Otsu Okay., Abrams J., Saeland S., Caux C., de Waal Malefijt R., de Vries J., Meyerson P. Isolation and characterization of an expressible cDNA encoding human IL-3. 24. Ida N., Sakurai S., Hosaka T., Hosoi K., Kunitomo T., Shimazu T., Maruyama T., Matsuura Y., Kohase M. Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis.

16. Conlon P. J., Luk K. H., Park L. S., March C. J., Hopp T. P., Urdal D. L. Generation of anti-peptide monoclonal antibodies which acknowledge mature CSF-2 alpha (IL 3) protein. 1. Abrams J. S., Pearce M. K. Development of rat anti-mouse interleukin 3 monoclonal antibodies which neutralize bioactivity in vitro. 52. Ziltener H. J., Clark-Lewis I., Fazekas de St Groth B., Hood L. E., Kent S. B., Schrader J. W. Antipeptide antibodies define the NH2-terminal structure of the pan-specific hemopoietin interleukin 3. J Immunol. 29. Kita H., Ohnishi T., Okubo Y., Weiler D., Abrams J. S., Gleich G. J. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. 13.Parajuli B, Acharya K, Yu R, Ngo B, Rashad AA, Abrams CF, et al. 18.Brewer CF, Miceli MC, Baum LG. IL-3 acts by binding to high affinity cell floor receptors current on hematopoietic cells. 41. Papayannopoulou T., Nakamoto B., Kurachi S., Tweeddale M., Messner H. Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretations. Two of those epitopes comprise the amino-terminal receptor binding domain. To corroborate these findings, we’ve additionally mapped the binding epitopes of 10 mAb of human or murine IL-3, and have outlined four distinct epitopes.

In this work, we realized for the primary time the synthesis of all four MMT/acyl-protected nucleo alanines, achieved by deprotection/reprotection of the newly synthesized Boc/acyl intermediates, helpful monomers for the obtainment of (alanyl-PNA)/DNA chimeras by situations totally compatible with the standard phosphoramidite DNA synthesis technique. New synthesis of PNA-3′DNA linker monomers, helpful constructing blocks to acquire PNA/DNA chimeras. Synthesis of peptide-oligonucleotide conjugates with single and a number of peptides attached to 2′-aldehydes by thiazolidine, oxime, and hydrazine linkages. 3. Antopolsky M, Azhayeva E, Tengvall U, Azhayev A. A basic methodology for the stepwise strong part synthesis of peptide-oligonucleotide conjugates. 2. Antopolsky M, Azhayev A. Stepwise stable phase synthesis of peptide-oligonucleotide phosphorothioate conjugates employing Fmoc peptide chemistry. 1996; Antopolsky and Azhayev 1999, 2000; Sakakura and Hayakawa 2000; Antopolsky et al. 1996; Diederichsen et al. 10. Diederichsen U. Alanyl-PNA: proof for linear band structures primarily based on guanine-cytosine base pairs. The enantiomeric purity was investigated for nucleo amino acid 7 (92% ee) as well as for all other derivatives described herein by Boc-deprotection followed by dipeptide formation with the Boc-l-Ala-OSu active ester and HPLC evaluation of the respective diastereomers.

The enantioselective preparation of all canonical alanyl nucleo amino acids with MMT-protected α-amino teams and acyl-protected exocyclic amino features of the nucleobases was offered for the first time on this work. An alanyl-PNA oligomer is based on a regular peptide backbone composed of alanyl amino acids that carry covalently linked nucleobases in β-place of the facet chain (Fig. 2) (Diederichsen 1997a, b). Nevertheless, intercalation might be made attainable by creating oligomers with a lacking base pair by introduction of glycines in opposite positions (Diederichsen 1997b). Evidence for a non-polar atmosphere inside the base stack of alanyl-PNA is derived from a stabilizing effect by incorporation of aromatic amino acids in alanyl-PNA (Diederichsen and Weicherding 1999). Shielding of the fluorophore from the water atmosphere when intercalated inside the alanyl-PNA duplex must be a major advantage of the chimeric alanyl-PNA/DNA molecular beacon. As identified already for the reaction with the unprotected nucleobases, the yield of the serine lactone ring opening with DNA bases is sort of low (22% in case of adenine) (Diederichsen et al.